Background And Objective: Measurement of carotid intima-media thickness (IMT) has been proposed for the evaluation of subclinical atherosclerosis as part of the cardiovascular prevention strategy. The objectives are to describe the association between IMT and the presence of other cardiovascular risk (CVR) factors and with CVR estimated by the SCORE function.
Subjects And Methods: Descriptive study in general population through non-probability sampling. There were 1,118 participants to whom we estimated their cardiovascular risk according to the SCORE function. We selected 467 participants who underwent carotid echo-doppler in which IMT was determined and carotid plaque was evaluated.
Results: Of the 467 individuals, 24, 49 and 27% belonged to the CVR, medium and high respectively. The population mean IMT was 0.63745 mm. The mean IMT for the cardiovascular risk groups low, medium and high was 0.5629, 0.66269 and 0.66016 mm respectively. IMT increased with age and was associated with other cardiovascular risk factors. In 13% of carotid ultrasound performed, atherosclerotic plaques were found. The highest percentage of individuals with atherosclerotic plaques were seen in the intermediate and high CVR groups.
Conclusions: The results of this study show similar values of carotid IMT and presence of carotid plaque in subjects of intermediate and high CVR. We also found an association between increased carotid IMT and age, weight and diabetes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medcli.2010.05.034 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dietary and Nutritional Aspects of Metabolic Syndrome Management: An Overview.
Endocr Metab Immune Disord Drug Targets
January 2025
Pharmacy Department, Tishk International University, Erbil, Kurdistan Region, Iraq.
Sedentary lifestyles and prolonged physical inactivity are often linked to poor mental and physical health as well as an increased risk of a number of chronic illnesses, including cancer, obesity, type 2 diabetes, and cardiovascular problems. Metabolic Syndrome (MetS), as the new disease, has emerged as the world's leading cause of illness. Despite having its roots in the West, this issue has now completely globalized due to the development of the Western way of life throughout the world.
View Article and Find Full Text PDFDelineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors.
Curr Drug Discov Technol
December 2024
Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu District, Tamilnadu, 603203, India.
Background: Clopidogrel, an antiplatelet drug commonly used in cardiovascular disease, is metabolized by the liver mainly through CYP2C19. Concomitant use of Proton pump inhibitors along with clopidogrel may affect the potency of clopidogrel by CYP2C19 inhibition. However, a novel PPI, ilaprazole is known to differ in its pharmacokinetic features, given the potential differences between ilaprazole's interactions and their metabolism with clopidogrel.
View Article and Find Full Text PDFEquitable Stroke Care for a Growing Population: The Need for Cultural Sensitivity.
Circ Cardiovasc Qual Outcomes
January 2025
Department of Medicine, Cardiovascular Division, University of Virginia Health, Charlottesville, Virginia, USA. (P.F.R.L., C.C.S.).
Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease.
Arterioscler Thromb Vasc Biol
January 2025
Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston. (B.C.-C., N.A.V.G., N.L.P., L.P.E., V.S.K.S., A.M.O., J.L., G.M., O.H., A.D., S.W.Y., C.A.I., K.C.O.M., S. Kotla, J.-i.A.).
Modulating immune function is a critical strategy in cancer and atherosclerosis treatments. For cancer, boosting or maintaining the immune system is crucial to prevent tumor growth. However, in vascular disease, mitigating immune responses can decrease inflammation and slow atherosclerosis progression.
View Article and Find Full Text PDFNationwide trends and outcomes of percutaneous coronary intervention for stable ischemic heart disease in end-stage kidney disease: a longitudinal study.
Ann Transl Med
December 2024
Department of Cardiovascular Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Background: Patients with end-stage kidney disease (ESKD) are at high risk for coronary artery disease. We investigate the trends and outcomes of percutaneous coronary intervention (PCI) for stable ischemic heart disease (SIHD) in patients with ESKD.
Methods: We utilized the United States Renal Data System [2010-2018] to include adult patients with ESKD on dialysis for at least 3 months who underwent PCI for SIHD.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!